Italian Journal of Dermatology and Venereology意大利皮肤病学与性病学杂志
Italian Journal of Dermatology and Venereology(英文缩写 ITAL J DERMATOL VENE),ISSN 2784-8671,eISSN 2784-8450,中文译名:意大利皮肤病学与性病学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 未收录 | N/A |
| 2022 | 1.900 | Q3 |
| 2023 | 1.800 | Q3 |
| 2024 | 2.600 | Q2 |
| 2025 | 2.100 | Q3 |
Italian Journal of Dermatology and Venereology 最新收录文献
-
1. Efficacy of picosecond Nd:YAG 1064 nm laser in melasma treatment: a real-world retrospective analysis.
PMID:日期:2026-09-21Melasma is a challenging hyperpigmentation disorder, especially prevalent in individuals with darker skin tones. Traditional treatments, like hydroquinone and chemical peels, have limitations due to high recurrence rates and post-inflammatory hyperpigmentation (PIH) risk. Picosecond lasers have emerged as promising alternatives for treating melasma in patients with Fitzpatrick skin types III-IV. This study aims to evaluate the efficacy and safety of the 1064 nm Nd:YAG picosecond laser for melasma in a Vietnamese population. This retrospective study analyzed 29 female patients with mild to very severe melasma treated using a 1064 nm Nd:YAG picosecond laser. Each patient received an initial toning procedure followed by a fractional treatment, across three sessions at four-week intervals. Outcome measures included MASI (Melasma Area and Severity Index), MELASQoL (Melasma Quality of Life), VISIA imaging and colorimetric assessments. Follow-up visits were conducted at 4, 8, and 12 weeks after the first treatment. Significant improvements were observed in MASI, MELASQoL, and pigmentation indices (L* and b*). VISIA analysis demonstrated significant reduction in superficial spots and brown spots, along with improvements in skin texture and wrinkles. Mild side effects were reported in 51.7% of patients, primarily erythema, which resolved spontaneously. No cases of PIH were documented. The 1064 nm Nd:YAG picosecond laser is an effective and safe treatment option for melasma in patients with Fitzpatrick skin types III-IV. Its ability to target melanin while minimizing thermal damage makes it particularly suitable for darker phototypes. Quantitative VISIA analysis supported treatment efficacy and revealed additional skin rejuvenation benefits. Further studies are required to assess long-term outcomes and recurrence rates.
-
3. Predictors of outcomes and satisfaction with tirbanibulin in actinic keratosis: a multicenter real-world study.
PMID:日期:2026-08-24Tirbanibulin 1% ointment is a short-course field therapy for actinic keratosis (AK). Real-world data on predictors of response, tolerability, and satisfaction may support patient selection and counselling. The aim was to evaluate effectiveness and tolerability in a large multicenter cohort, identify predictors of high clinical clearance and local skin reactions (LSRs), and describe patient and physician satisfaction. This retrospective observational real-life study (33 Italian dermatology centers) included 679 patients. Clinical response was classified as complete (100%), good (75-99%), moderate (50-74%), or <50% clearance; high clearance was defined as ≥75%. AK severity was assessed using AK Area and Severity Index (AKASI). LSRs were graded 0-4, and a total score was calculated. Satisfaction was rated 0-4 (scores 3-4 indicated high satisfaction.) Multivariable logistic regression identified predictors of high clearance, erythema, and vesiculation/pustulation. Patients were predominantly male (70.8%), mean age 74.9±9.7 years; 77.6% were AK-experienced. All patients completed treatment. High clearance occurred in 69.7% and was greater in AK-naïve patients (78.3% vs. 67.1%, P<0.001). Mean AKASI decrease was 63.2%; photodamage improvement was 30.5%. Tolerability was favorable (mean LSR score 0.65±0.90); 11.9% of LSRs were ≥3, with no grade 4 vesiculation/ulceration occurring. Lower Olsen grade independently predicted high clearance. Female sex and age ≥75 years were associated with higher odds of selected LSRs. High satisfaction was reported by 79.4% of patients and 83.1% of physicians. Tirbanibulin 1% achieved high clearance with favorable tolerability and satisfaction, supporting its use in individualized management of field cancerization.
-
4. Topical treatment of psoriasis with calcipotriol/betamethasone dipropionate cream in real-life clinical practice: expert opinion.
PMID:日期:2026-08-24The fixed-dose combination of calcipotriol and betamethasone dipropionate (Cal/BDP) is an established topical psoriasis treatment. The cream formulation of Cal/BDP has been found effective and well-tolerated for the treatment of mild-to-moderate disease, with high levels of patient satisfaction. The aim of this consensus document is to guide optimal real-life use of Cal/BDP cream in patients with psoriasis. Eight hospital-based dermatologists, with long-standing experience in psoriasis treatment, developed a consensus document on three topics (therapeutic protocols and schedules; high-impact areas; and treatment adherence) regarding the use of Cal/BDP cream in clinical practice. A modified Delphi process was used to achieve consensus among panel members. Statements with treatment recommendations, based on the experts' opinions and experience, as well as an analysis of relevant published data, were elaborated on and discussed during two meetings occurring two months apart. Full agreement among panel members was obtained after two online Delphi rounds. As seen in clinical trials, Cal/BDP cream monotherapy has proved beneficial in the treatment of mild to moderate plaque psoriasis. However, it can also be used as an adjunct to systemic/biologic drug treatment or as long-term maintenance therapy. Cal/BDP cream also plays an important role in the treatment of psoriasis on high-impact sites (including the scalp, peripheral facial areas, skin folds and palmoplantar areas) with treatment schedules varying according to disease severity and area involved. Due to its vehicle, treatment with Cal/BDP cream is associated with high levels of treatment convenience and patient acceptability, positively impacting adherence. Cal/BDP cream can be used safely and effectively for the treatment of psoriasis in a range of clinical presentations. Its favorable cosmetic characteristics contribute to treatment success by enhancing patient adherence. Studies on the long-term use of Cal/BDP cream as a maintenance therapy are needed.
-
6. Organization of skin ulcer outpatient clinics in Italy: results from a survey of the Study Group on Ulcers of the Italian Society of Dermatology and Venereology.
PMID:日期:2026-08-01Chronic skin ulcers represent a significant burden for healthcare systems due to their high prevalence, prolonged healing times and recurrence rates. Despite their impact, the organization and resources of outpatient ulcer clinics remain poorly characterized worldwide. The aim of this study was to evaluate the organization of outpatient clinics for chronic skin ulcers in the Italian dermatological setting. A survey was distributed to all the members of the Study Group on Cutaneous Vascular Diseases and Skin Ulcers of the Italian Society of Dermatology and Venereology. The survey collected data on outpatient service organization, multidisciplinary involvement, nursing support, services provided, and patient volume. Thirty-nine clinicians from 10 centers participated. Nine centers reported dedicated outpatient dermatologic ulcer clinics, with approximately two thirds (6/9) integrating multidisciplinary approaches. The services operate an average of three days per week and manage approximately 13-14 patients per day (mean:13.5). Universally available services at ulcer outpatient clinics include dermatological consultation, wound care (curettage, simple dressings, advanced dressings) and specialized nursing staff. Further widely performed diagnostic and therapeutic procedures include microbiological swabs, skin biopsy and vascular consultation. More advanced services are available only in selected centers. This study highlights significant variations in the organization and resources of outpatient ulcer clinics among participating centers. Addressing these disparities through standardized protocols, equitable resource allocation, and integration of advanced tools is essential to improve patient care and outcomes.
-
7. Hidradenitis suppurativa-associated squamous cell carcinoma: a systematic review of clinical, molecular, and risk factor insights.
PMID:日期:2026-08-01Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the pilosebaceous unit that can rarely harbor squamous cell carcinoma (SCC). Despite its clinical relevance, comprehensive characterization of HS-SCC - including risk factors, histological and molecular features, and outcomes - remains limited. A systematic review of the literature was performed to identify all published cases of HS-associated SCC. Data on demographics, HS features, tumor characteristics, human papillomavirus (HPV) status, treatments, and outcomes were extracted to identify risk phenotypes and prognostic factors. A total of 174 cases were included. Most patients were male (78.4%), with a mean age of 53 years, and nearly all presented Hurley stage III HS affecting the lower trunk, predominantly the gluteal region. Tumors were generally large, often arising from sinus tract epithelium, and were commonly well-differentiated. HPV infection was detected in 28.6% of cases, predominantly HPV-16. Metastasis occurred in 54.3% of patients. Overall mortality was 52.8%, with mean survival until death of 11.9 months. Male sex, gluteal location, poor histologic differentiation, and presence of metastasis were associated with worse outcomes. Risk phenotypes include males >50 years, long-standing HS (>10 years), Hurley III disease with complex sinus tracts involving the lower trunk; in females, vulvar involvement is an additional risk factor. HS-SCC is rare but highly aggressive. Early recognition of high-risk phenotypes, regular monitoring of chronic HS lesions, timely surgery, and imaging assessment are essential to improve outcomes. HPV vaccination may offer preventive benefits in susceptible patients.
-
8. Eosinophilic fasciitis: a comprehensive systematic review of clinical, histologic, and therapeutic perspectives.
PMID:日期:2026-08-01Eosinophilic fasciitis (EF) is a rare autoimmune disorder within the sclerodermatous disease spectrum, characterized by inflammation and fibrosis of the subcutaneous fat and fascia, often accompanied by peripheral eosinophilia. Although its exact etiology remains uncertain, potential triggers include intense physical exertion, infections, malignancies, and drug exposure - most recently, immune checkpoint inhibitors such as anti-PD-1/PD-L1 agents. Histopathological findings consistently reveal eosinophilic infiltration and fibrosis of subcutaneous fat and fascia. Corticosteroids remain the cornerstone of treatment, often supplemented with immunosuppressants in refractory cases. Emerging therapies, such as anti-IL-5 agents (mepolizumab and benralizumab), offer targeted approaches for corticosteroid-resistant EF by directly modulating eosinophilic inflammation. A systematic review of PubMed and Ovid was conducted according to PRISMA guidelines until October 2024, including studies on clinical, histological, or therapeutic aspects of eosinophilic fasciitis. The mean age was 45.95 years, with balanced sex distribution (51.1% females). Most cases involved both upper and lower limbs (56.2%), followed by lower limbs (11.2%) and upper limbs alone (9.8%). Eosinophilia was present in 92.4% of patients, hypergammaglobulinemia in 19.9%, and elevated CRP in 13.5%. Histology showed eosinophilic infiltration in 68.9%. Identifiable triggers included intense exercise (8.7%), drugs - especially anti-PD1 checkpoint inhibitors (5.6%) - infections (2.8%), and paraneoplastic causes (2.3%). Treatments included corticosteroids (89.3%), methotrexate (27.5%), cyclosporine (6.7%), hydroxychloroquine (3.6%), azathioprine (3.9%), and rituximab (1.7%). Anti-IL5 agents (N.=7) were used in refractory cases, with full resolution in 2 and mild improvement in 5. This review provides a systematic analysis of the clinical, biological, and histological characteristics of EF, its associated triggers, and therapeutic strategies based on a comprehensive review of reported cases. We found that poor prognostic factors include diagnostic delay (>6 months), trunk involvement, early-onset disease (<12 years), and morphea-like skin lesions.
-
9. Oral isotretinoin and acne clearance: the role of daily dosage in a real-world clinical setting.
PMID:日期:2026-08-01Complete acne resolution with oral isotretinoin has not been specifically addressed. We aimed to assess the achievement of acne clearance with particular focus on oral isotretinoin daily dosage. This single-center, retrospective study included a cohort of acne patients treated with oral isotretinoin at our Acne Clinic between January 2014 and December 2023. The key aspects investigated were the rate of patients who achieved acne clearance at face, chest and back, the incidence of adverse effects and the relevance of the daily oral isotretinoin dosage in relation to these two outcomes. Of the 359 patients included (61.3% males, 38.7% females), 217, 61.6% of those with facial involvement, achieved complete clearance of face acne, 101 (46.1%) achieved clearance of back acne and 89 (75.4%) a complete recovery of chest acne. A mean daily dosage between >10 and 20 mg was associated with a higher probability of complete resolution of acne, especially at chest, compared to lower dosages. Mean daily doses higher than 20 mg were not associated with a greater probability of clearance compared to lower dosages, while they were associated with an increased side effects' occurrence. The daily dosage of oral isotretinoin does not appear to be a determining factor in achieving acne clearance, while it may influence the incidence of side effects. A mean daily dosage ranging from >10 to 20 mg may represent an optimal balance, ensuring therapeutic efficacy while limiting the risk of adverse events.
-
10. Primary cutaneous lymphomas in children: a single-center retrospective analysis and narrative review of the literature.
PMID:日期:2026-08-01Primary cutaneous lymphomas (PCLs) are uncommon in children, with mycosis fungoides (MF), lymphomatoid papulosis (LyP), and primary cutaneous small/medium CD4+ T-cell lymphoproliferative disorder (PCSM-TCLPD) representing the most frequent entities. Due to their rarity, available data derive mainly from case reports and small series, and diagnostic delays are frequent. This study aimed to describe the clinical, histopathological, and therapeutic features of pediatric PCLs in a single Italian referral centre and compare them with the literature evidence. We conducted a single-center, retrospective observational study including patients aged ≤16 years with a histologically confirmed diagnosis of PCLs, followed for at least six months at the Dermatology Unit of the University Hospital of Bologna between 2002 and 2024. Clinical, histological, therapeutic, and follow-up data were collected and analyzed. Among 354 PCL patients, 10 pediatric cases were identified: six MF, three LyP, and one PCSM-TCLPD. The mean age at diagnosis was 9.1 years. MF cases were mostly early-stage (IA, 5/6), with folliculotropic (67%), hypopigmented (50%), and classic (50%) variants; all were treated with topical corticosteroids and/or PUVA, with good long-term outcomes (67% complete remission). LyP patients presented at younger ages (mean 5.7 years) with type A (N.=2) and D (N.=1) subtypes; all achieved complete remission despite recurrences, one requiring methotrexate. The single PCSM-TCLPD case was cured with surgical excision. After a mean follow-up of 8.2 years, all patients were alive, most disease-free. Pediatric PCLs are rare but generally indolent, with an excellent prognosis. However, their clinical heterogeneity and diagnostic delay highlight the importance of early biopsy, integrated clinicopathological assessment, and long-term follow-up. Multicenter studies are needed to establish tailored treatment algorithms for children.